InspireMD, Inc. filed a Form 8-K on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, for an underwritten public offering expected to raise approximately $37.5 million in gross proceeds.

Key Highlights

  • Offering size: The company estimates gross proceeds of approximately $37.5 million, or approximately $43.1 million if the over-allotment option is exercised in full, prior to deducting underwriting discounts, commissions, and estimated offering expenses.
  • Securities offered: 7,342,308 shares of common stock and pre-funded warrants to purchase up to 50,350,000 shares, each paired with Series L common warrants to purchase up to 43,269,231 shares in aggregate.
  • Pricing: Each share and accompanying common warrant is priced at a combined public offering price of $0.65; each pre-funded warrant and accompanying common warrant is priced at $0.6499.
  • Underwriting discount: The company agreed to pay the underwriters a discount equal to 6.0% of gross proceeds, plus reimbursement of the representative's expenses up to $125,000.
  • Over-allotment option: The representative received a 30-day option to purchase up to 8,653,846 additional shares and/or pre-funded warrants, representing 15% of the total securities sold.
  • Warrant terms: Each common warrant has an exercise price of $0.65 per share, is immediately exercisable, and expires one year from the date of issuance; each pre-funded warrant has an exercise price of $0.0001 per share and is exercisable at any time until exercised in full.
  • Use of proceeds: According to the filing, the company intends to use net proceeds for operations, "including, but not limited to, research and development, sales and marketing, working capital and other general corporate purposes."

InspireMD Enters Underwriting Agreement With Lake Street Capital Markets for November 2026 Offering

According to the filing, InspireMD, Inc. (NASDAQ:NSPR) entered into an underwriting agreement on November 13, 2026, with Lake Street Capital Markets, LLC as representative of the several underwriters. The agreement covers the issuance and sale of common stock, pre-funded warrants, and Series L common warrants in an underwritten public offering. The closing of the offering is expected to occur on or about November 16, 2026, subject to customary closing conditions, the filing stated.

The common warrants will be issued pursuant to a warrant agency agreement dated November 12, 2026, between the company and Securities Transfer Corporation as warrant agent, the filing disclosed. Holders are subject to a beneficial ownership cap: no portion of any warrant may be exercised to the extent it would cause the holder, together with affiliates and attribution parties, to beneficially own more than 4.99% (or, at the holder's election, 9.99%) of outstanding common stock immediately after exercise.

The filing noted that the offering is being made pursuant to the company's effective shelf registration statement on Form S-3 (No. 333-286309), filed with the SEC on April 1, 2025, and effective April 10, 2025. Lock-up restrictions apply: subject to certain exceptions, the company agreed not to issue or sell common stock or convertible securities for 60 days following the closing without the representative's prior written consent, and not to enter into variable rate transactions for six months following closing. Executive officers and directors also agreed not to sell or transfer common stock or convertible securities for 60 days from the date of the underwriting agreement.

What Was Disclosed

InspireMD disclosed the terms of an underwriting agreement for a public offering of common stock, pre-funded warrants, and common warrants, with estimated gross proceeds of approximately $37.5 million, priced on November 13, 2026, and expected to close on or about November 16, 2026.